Warnex will be forced to leave Toronto exchange next month

By Gareth Macdonald

- Last updated on GMT

Related tags: Toronto stock exchange, Stock market

Contract services firm Warnex will leave the Toronto Stock Exchange (TSX) after failing to meet the requirements for continued listing.

According to a TSX statement issued last week​ the Quebec, Canada-based contractor – which provides a range of preclinical and trial-stage bioanalytical testing and analysis services to biopharma customers - will delist after the market closes on February 13.

In response Warnex said it is “actively exploring ways to maintain the value and liquidity of its Common Shares, including seeking a listing of its Common Shares on an alternative exchange​.”

A Warnex spokeswoman told Outsourcing-pharma.com the company is unable to comment further and reiterated executive committee member Michael Singer's statement that Warnex is "currently under a strategic review and will update the market only at such time it has a material development​."

Warnex has been under TSX scrutiny since August​ when it fell short of the exchange's listing requirement of a market capitalisation of C$3m after two consecutive quarters​ of low drug industry demand for analytical, quality control and laboratory services reduced its revenue and earnings.

In the months since August the firm has sought to turn things around, primarily by establishing an independent review committee to assess the viability of ongoing operations.

Subsequently, Warnex sold its medical labs arm​ to Gamma-Dynacare Medical Laboratories for C$7.5m (EUR5.8m) and - more recently - has agreed to divest its analytical services business to an unnamed industry buyer​.

In the period Warnex also waved goodbye to long-serving company president and CEO Mark Busgang​ who tendered his resignation in November.

Quite what Warnex can do to further restructure its operations in light of the TSX delisting is unclear given that – when the $1.1m (€851,291) sale of its analytical services sale completes later this week​ – its only remaining division will be its bioanalytical services business.

Related news

Show more

Related products

show more

Has EDC Kept Up With Changes In Clinical Trials?

Has EDC Kept Up With Changes In Clinical Trials?

Oracle Health Sciences | 14-Dec-2020 | Technical / White Paper

In just a few decades, clinical trials have changed dramatically. Twenty years ago, most of the data used in clinical research was entered on paper, but...

Liver Disease Capabilities

Liver Disease Capabilities

Q² Solutions | 01-Oct-2020 | Clinical Study

We integrate therapeutic insights, state-of-the-art technologies, best-in-class methods and quality systems to optimize NAFLD & NASH study design,...

CAR-T Cell Therapy

CAR-T Cell Therapy

Q² Solutions | 01-Sep-2020 | Clinical Study

Cell therapy involves the transfer of genetically altered cells into a patient. As a global central laboratory services organization, we provide testing...

Related suppliers

Follow us

Products

View more

Webinars